Exploring how nasal anti-CD3 treatment protects the brain in Alzheimer's disease models
Official title: Mechanisms underlying the neuroprotective effect of nasal administration of anti-CD3 in AD mouse models
Funded at Brigham and Women's Hospital · NIH-11170759 · Data updated 2026-11-12
This study is looking at how a nasal treatment with anti-CD3 might help reduce brain inflammation and improve thinking skills in mice with Alzheimer's disease by changing how certain immune cells work in the brain.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 15, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $789,540 |
| NIH project number | 5R01AG084596-02 |
| Project ID | NIH-11170759 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would be individuals with early-stage Alzheimer's disease or those at risk of developing the condition.
✕Less likely to help
Patients with advanced Alzheimer's disease or those with other forms of dementia may not benefit from this research.
What this research studies
This research investigates the effects of nasal administration of anti-CD3 on neuroinflammation in mouse models of Alzheimer's disease. It focuses on how this treatment can alter the behavior of immune cells in the brain, specifically microglia and astrocytes, which are involved in the disease process. By inducing regulatory T cells that migrate to the brain, the study aims to reduce neuroinflammation and improve cognitive function. The research utilizes advanced mouse models to assess the potential benefits of this innovative approach.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that improve cognitive function and reduce neuroinflammation in Alzheimer's disease.
How similar studies have gone: Previous research has shown promising results with similar approaches in animal models, indicating potential for success in this novel treatment strategy.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Weiner, Howard L — Brigham and Women's Hospital
- Study coordinator: Weiner, Howard L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.